According to the lawsuit, the Registration Statement contained false and/or misleading statements and/or failed to disclose that:

• Kenvue faces potential headwinds as a result of confirmed concerns about the efficacy of phenylephrine  (or “PE”) , which it knew or should have known;
• Kenvue did not discuss risks relating to the efficacy of phenylephrine in its IPO, the utility of which had been questioned since at least 2007;
• while Kenvue disclosed risks relating to litigation, it did not disclose specific risks relating to potential litigation arising from adverse findings on the efficacy of phenylephrine; and
• as a result, defendants’ public statements were materially false and misleading at all relevant times and negligently prepared.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Attorney Advertising. Prior results do not guarantee a similar outcome.